title: Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis.
abstract: BACKGROUND
  The costs of infusion versus bolus administration of chemotherapy has been a point of controversy as has been the method of quantitating the cost. The present study analyzes the reimbursement for chemotherapy administration by infusion compared with bolus delivery based on reimbursement and relates this to cost based on projected charges and actual charges in a private practice setting.
  
  
  METHODS
  Actual reimbursement records were retrieved for selected patients receiving infusion or bolus administration of specific chemotherapy regimens for three tumors: colon carcinoma, breast carcinoma, and lymphoma. All services were included except for radiology and hospitalization. Medicare reimbursement represented 90% of the treatment cycles analyzed.
  
  
  RESULTS
  Actual reimbursement per month for each infusion regimen was as follows: colon carcinoma, $528 (5-fluorouracil [5-FU]); breast carcinoma, $621 (doxorubicin and cyclophosphamide [AC]) and $685 (cyclophosphamide, methotrexate, and fluorouracil [CMF]); and lymphoma, $603 (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP]). Actual reimbursement per month for a bolus regimen was colon carcinoma, $393 (5-FU + leucovorin); breast carcinoma, $991 (AC) or $453 (CMF); and lymphoma, $749 (CHOP). Actual reimbursement represents 21-36% of actual charges. Projected charges based on the model system are generally less than the actual charges.
  
  
  CONCLUSIONS
  The cost of chemotherapy as defined by reimbursement are substantially less than actual charges and are also less than projected costs based on charges. Data comparing bolus versus infusion reimbursement costs for colon carcinoma, breast carcinoma, and lymphoma indicate that differences between reimbursement for bolus and infusion administration are not substantial.
authors.affiliation: Cancer Center of Boston, MA 02128, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Lokich
authors.forename: C L
authors.initials: CL
authors.lastname: Moore
authors.forename: N R
authors.initials: NR
authors.lastname: Anderson
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000191:economics; D000931:Antidotes / Q000008:administration & dosage / Q000191:economics; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000191:economics; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000191:economics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000191:economics*; D001943:Breast Neoplasms / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D003365:Costs and Cost Analysis; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000191:economics; D004317:Doxorubicin / Q000008:administration & dosage / Q000191:economics; D005252:Fees, Pharmaceutical; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000191:economics; D006801:Humans; D007262:Infusions, Intravenous / Q000191:economics; D007275:Injections, Intravenous / Q000191:economics; D002955:Leucovorin / Q000008:administration & dosage / Q000191:economics; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D006278:Medicare / Q000191:economics; D008727:Methotrexate / Q000008:administration & dosage / Q000191:economics; D011241:Prednisone / Q000008:administration & dosage / Q000191:economics; D011331:Private Practice / Q000191:economics; D012051:Reimbursement Mechanisms; D014481:United States; D014750:Vincristine / Q000008:administration & dosage / Q000191:economics
chemical_list: D000903:Antibiotics, Antineoplastic; D000931:Antidotes; D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate